KeyBanc Downgrades Simulations Plus (SLP) Stock to Sector Weight

Simulations Plus, Inc. (NASDAQ:SLP) has recently faced a downgrade from KeyBanc, shifting its stock status to “Sector Weight” from “Overweight” without a specified price target. This adjustment comes amidst ongoing challenges in the biopharma end market environment, impacting Simulations Plus more significantly due to customer concentration and biotech exposure. KeyBanc anticipates continued weak customer demand in the near-to-middle-term, prompting this adjustment.

In Q3 of 2025, Simulations Plus, Inc. witnessed a 10% increase in revenue, aligning with preliminary expectations. The company’s software revenue showed a 6% rise, driven by the success of its ADMET Predictor® software and modest growth in GastroPlus® and MonolixSuiteTM software. Additionally, services revenue saw a notable 17% increase, primarily attributed to the strong performance in Medical Communications services.

During this quarter, Simulations Plus, Inc. underwent a strategic reorganization, transitioning from a business unit structure to a functionally driven operating model. This realignment marked the final phase of a multi-year transformation aimed at streamlining operations, unlocking synergies, and focusing resources on promising growth opportunities. For the full fiscal year 2025, the company anticipates revenue ranging between $76 million to $80 million.

In a recent investor letter, Wasatch Global Investors expressed their views on Simulations Plus, Inc. as the strategy’s largest detractor. While acknowledging the company’s consistent growth and margin expansion track record, concerns were raised regarding the funding environment for biotechnology and pharmaceutical companies. Wasatch Global Investors reduced its position in Simulations Plus due to worries linked to the company’s recent acquisition strategy, though they remain confident in the core business’s growth potential.

Simulations Plus, Inc. operates in the software industry, developing and producing software for pharmaceutical research, education, and providing consulting and contract research services to the broader pharmaceutical sector. While acknowledging the investment potential of SLP, other AI stocks may offer greater upside potential with less downside risk. For investors seeking undervalued AI stocks with significant growth potential, exploring alternative options may be beneficial.

In conclusion, Simulations Plus, Inc. continues to navigate market challenges and strategic transformations to position itself for future growth opportunities. As the company adapts to evolving industry dynamics, investors may consider a diversified approach to capitalize on emerging trends and investment prospects in the AI sector.